Stockreport

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses [Yahoo! Fin...

Cel-Sci Corporation  (CVM) 
NASDAQ:AMEX Investor Relations: cel-sci.com/investor_relations.html
PDF survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival A third-party head and neck cancer study publ [Read more]